A mutant of a steroid hydroxylase, a recombinant yeast strain, substrate and applications

By modifying CYP103168 enzymes, mutants L1 (H121A) and L2 (S367A) were designed to optimize the catalytic selectivity of steroid hydroxylases in Saccharomyces cerevisiae. This solved the problems of poor regioselectivity and stereospecificity of steroid C11β-hydroxylation, and enabled the efficient production of 11β,17α-dihydroxyprogesterone, supporting a new production route for hydrocortisone.

CN116716266BActive Publication Date: 2026-11-17SHANGHAI JIAOTONG UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202310861356.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-07-13
Publication Date
2026-11-17
Estimated Expiration
2043-07-13

AI Technical Summary

Technical Problem

In existing technologies, steroid hydroxylases exhibit poor regioselectivity and stereospecificity in catalyzing steroid C11β-hydroxylation, making it difficult to achieve efficient steroid C11β-hydroxylation.

Method used

Enzyme engineering was performed on the cytochrome P450 enzyme CYP103168 to design mutants L1 (H121A) and L2 (S367A), which were then introduced into Saccharomyces cerevisiae to optimize the regioselectivity and stereospecificity of its catalytic steroid C11β-hydroxylation. Using 17α-hydroxyprogesterone as a substrate, 11β,17α-dihydroxyprogesterone was formed.

Benefits of technology

It significantly improved the regioselectivity and stereospecificity of C11β-hydroxylation of steroid hydroxylase from 20% to nearly 100%, providing a highly efficient intermediate for the production of hydrocortisone and opening up a new production route.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116716266B_ABST
    Figure CN116716266B_ABST
Patent Text Reader

Abstract

This invention discloses a mutant of steroid hydroxylase, a recombinant yeast strain, a substrate, and its applications, relating to the field of genetic engineering. The mutant of steroid hydroxylase includes mutant L1 and / or mutant L2. The amino acid sequence of mutant L1 is shown in SEQ ID NO: 3 in the sequence listing, and the amino acid sequence of mutant L2 is shown in SEQ ID NO: 5 in the sequence listing. The recombinant yeast strain is obtained by introducing mutant L1 and / or mutant L2 into *Saccharomyces cerevisiae*. The substrate of the steroid hydroxylase is the steroid compound 17α-hydroxyprogesterone. The invention also discloses the application of the mutant of steroid hydroxylase, the recombinant yeast strain, and the substrate in catalyzing the hydroxylation of steroidal C11β-positions. This invention obtains highly specific 11β-hydroxylated products by modifying steroid hydroxylase through changing the substrate type and / or enzyme engineering.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of genetic engineering, and more particularly to a mutant of a steroid hydroxylase, a recombinant yeast strain, a substrate, and its applications. Background Technology

[0002] Steroids are a class of small organic molecules with cyclopentane-hydrophenanthrene as their core, widely distributed in nature. Steroid hormones are the second largest class of drugs after antibiotics, playing an important regulatory role in the body. They are mainly divided into two categories: sex hormones and adrenocortical hormones, and are used clinically to treat cardiovascular diseases, lymphocytic leukemia, tumors, and endocrine disorders [Donova MV, Egorova O V. Microbial steroid transformations: current state and prospects[J]. Applied Microbiology and Biotechnology, 2012, 94(6):1423-1447.]. Currently, more than 400 steroid drugs have been approved. Among them, hydrocortisone is an effective anti-inflammatory drug and an important intermediate in the synthesis of other steroid drugs, such as prednisolone, dexamethasone, and betamethasone. The hydroxyl group at the C11β position of this type of steroid drug is crucial for the biological activity of glucocorticoids and is also the key challenge in synthesizing these compounds.

[0003] Currently, introducing hydroxyl groups at the C11β position of the steroid skeleton is difficult to achieve through chemical synthesis, and industrially it mainly relies on microbial transformation. Commonly used industrial strains for steroid C11β hydroxylation include *Absidia orchidis* and *Curvularia lunata* [Felpeto-Santero C, Galán B, Luengo JM, Fernández- JM, Del Cerro C, Medrano FJ, García J L. Identification and expression of the 11β-steroid hydroxylase from Cochliobolus lunatus in Corynebacterium glutamicum[J]. Microb Biotechnol, 2019, 12(5): 856-868.], but they are all affected by interference from other genes in the strain, resulting in poor regional and stereoselectivity and many byproducts. For example, when *Absidia orchidis* catalyzes 17α-hydroxyprogesterone-21-acetate (RSA), it generates about 50% of 11α-OH epihydrocortisone and 50% of 11β-OH hydrocortisone[Chen J, Fan F, Qu G, Tang J, Xi Y, Bi C, Sun Z, Zhang X. Identification of Absidia orchidis steroid 11β-hydroxylation system and its application in engineering [Saccharomyces cerevisiae for one-step biotransformation to produce hydrocortisone[J]. Metab Eng, 2020, 57: 31-42.]. Researchers have also attempted to use biotechnology to discover enzymes with steroid C11β-hydroxylation activity and introduce their encoding genes into heterologous hosts such as yeast for expression, hoping to obtain strains with highly specific catalytic ability to catalyze steroid C11β-hydroxylation. However, so far there have been no very successful cases.

[0004] The cytochrome P450 enzyme CYP103168 involved in this invention is derived from C. lunatus ATCCTM12017 and has been identified as possessing steroidal C14α and C11β hydroxylation capabilities, with significant differences in regioselectivity for different steroidal substrates. It has been reported that CYP103168 exhibits a regioselectivity of up to 99% in catalyzing the formation of 14α-OH-AD from androstenedione (AD), while its regioselectivity is very poor when catalyzing 11-deoxycortisone (RSS), simultaneously generating approximately 40% of 14α-OH-RSS and 60% of 11β-OH-RSS, with the presence of 11α-OH-RSS as a byproduct.

[0005] Therefore, those skilled in the art are dedicated to developing a technical solution to improve the specificity of steroid hydroxylase in catalyzing steroid C11β-hydroxylation. Summary of the Invention

[0006] In view of the above-mentioned deficiencies of the prior art, the technical problem to be solved by the present invention is how to improve the specificity of steroid hydroxylase in catalyzing steroid C11β-hydroxylation.

[0007] To achieve the above objectives, the present invention provides a mutant of steroid hydroxylase, including mutant L1 and / or mutant L2, wherein the amino acid sequence of mutant L1 is shown as SEQ ID NO: 3 in the sequence listing, and the amino acid sequence of mutant L2 is shown as SEQ ID NO: 5 in the sequence listing.

[0008] Furthermore, the nucleotide sequence encoding mutant L1 is shown in SEQ ID NO: 4 in the sequence listing, and the nucleotide sequence encoding mutant L2 is shown in SEQ ID NO: 6 in the sequence listing.

[0009] A recombinant yeast strain with a mutant of steroid hydroxylase, the recombinant yeast strain being obtained by introducing mutant L1 and / or mutant L2 into Saccharomyces cerevisiae.

[0010] Furthermore, the culture medium for the brewer's yeast was a uracil auxotroph.

[0011] The present invention also provides a substrate for a steroid hydroxylase, namely the steroid compound 17α-hydroxyprogesterone.

[0012] Furthermore, highly specific 11β-hydroxylated products were obtained by changing the substrate type.

[0013] The present invention also provides an application of a mutant of steroid hydroxylase in catalyzing the hydroxylation of steroid C11β.

[0014] This invention also provides the application of a recombinant yeast strain of steroid hydroxylase in catalyzing the hydroxylation of steroid C11β.

[0015] Furthermore, the substrates for catalyzing the C11β-hydroxylation of steroids include 17α-hydroxyprogesterone series steroid compounds, and the products include 11β,17α-dihydroxyprogesterone series steroid compounds.

[0016] The present invention also provides a substrate for steroid hydroxylase, namely the application of the steroid compound 17α-hydroxyprogesterone in the steroid hydroxylase-catalyzed hydroxylation of the C11β position of steroid.

[0017] Furthermore, steroid hydroxylases include steroid hydroxylase CYP103168 and its mutants, the amino acid sequence of which is shown in SEQ ID NO: 1 in the sequence listing.

[0018] The present invention also provides the use of an 11β,17α-dihydroxyprogesterone steroid compound as an intermediate in the production of hydrocortisone.

[0019] In a preferred embodiment 1 of the present invention, the production process route of hydrocortisone is described in detail.

[0020] In another preferred embodiment 2 of the present invention, the construction process of the pESC-CYP103168 recombinant Saccharomyces cerevisiae vector is described in detail.

[0021] In another preferred embodiment 3 of the present invention, the construction process of mutant plasmids L1 (H121A) and L2 (S367A) is described in detail.

[0022] In another preferred embodiment 4 of the present invention, the transformation and screening of recombinant yeast are described in detail;

[0023] In another preferred embodiment 5 of the present invention, yeast cell catalysis and result detection are described in detail.

[0024] The beneficial technical effects of this invention are as follows:

[0025] This invention discloses a technical solution for obtaining highly specific 11β-hydroxylated products by changing the substrate type of steroid hydroxylase, or by improving the regioselectivity and stereospecificity of steroid hydroxylase from 20% to nearly 100% through enzyme engineering modification of steroid hydroxylase.

[0026] The following will further explain the concept, specific structure, and technical effects of the present invention in conjunction with the accompanying drawings, so as to fully understand the purpose, features, and effects of the present invention. Attached Figure Description

[0027] Figure 1 This is a schematic diagram of the hydrocortisone production process route of a preferred embodiment 1 of the present invention;

[0028] Figure 2 This is a diagram illustrating the construction of the pESC-CYP103168 recombinant Saccharomyces cerevisiae expression vector, which is a preferred embodiment 2 of the present invention.

[0029] Figure 3 This is a diagram of enzyme digestion verification of the pESC-CYP103168 recombinant expression vector plasmid in a preferred embodiment 3 of the present invention;

[0030] Figure 4 This is an agarose gel electrophoresis image of the PCR amplification bands of the L1 (H121A) and L2 (S367A) mutant plasmids of a preferred embodiment 3 of the present invention;

[0031] Figure 5This is a UPLC detection result of 17α-hydroxyprogesterone transformed by recombinant wild-type bacteria, mutants L1 (H121A) and L2 (S367A) in a preferred embodiment of the present invention. Detailed Implementation

[0032] The following description, with reference to the accompanying drawings, illustrates several preferred embodiments of the present invention to make its technical content clearer and easier to understand. The present invention can be embodied in many different forms, and the scope of protection of the present invention is not limited to the embodiments mentioned herein.

[0033] Example 1: Production process route of hydrocortisone

[0034] The cytochrome P450 enzyme CYP103168 involved in this invention is derived from C. lunatus ATCCTM12017 and has been identified as having both steroid C14α and C11β hydroxylation capabilities, with significant differences in regioselectivity for different steroid substrates. It has been reported that CYP103168 has a high regioselectivity of up to 99% when catalyzing androstenedione (AD) to generate 14α-OH-AD, while its regioselectivity is very poor when catalyzing 11-deoxycortisone (RSS), generating about 40% of 14α-OH-RSS and 60% of 11β-OH-RSS at the same time, and there are also 11α-OH-RSS byproducts [Chen J,Tang J,XiY,Dai Z,Bi C,Chen X,Fan F,Zhang X.Production of 14α-hydroxysteroids by arecombinant Saccharomyces cerevisiae biocatalyst expressing of a fungalsteroid 14α-hydroxylation system[J].Appl Microbiol Biotechnol,2019,103(20):8363-8374.].

[0035] Based on the above background, this invention utilizes the substrate-dependent regio- and stereoselectivity of CYP103168 in catalyzing steroid hydroxylation, screening 17α-hydroxyprogesterone as the substrate for this enzyme, and improving the regioselectivity of the enzyme in catalyzing steroid C11β-hydroxylation to 95%. Subsequently, using computer-aided design methods such as homology modeling, CYP103168 was semi-rationally engineered to further enhance its regioselectivity and stereospecificity in catalyzing C11β-hydroxylation to nearly 100%. The encoding genes of CYP103168 and its corresponding mutants, L1 (H121A) and L2 (S367A), were introduced into *Saccharomyces cerevisiae*, thereby obtaining a recombinant yeast strain capable of highly specific transformation of 17α-hydroxyprogesterone series steroidal compounds into 11β,17α-hydroxyprogesterone series steroidal compounds. 11β,17α-dihydroxyprogesterone can serve as an important intermediate in the production of hydrocortisone, providing a breakthrough technological foundation for opening up new production routes for hydrocortisone-like steroidal drugs. The hydrocortisone production process is as follows: Figure 1 As shown, pathway a is a highly efficient and specific catalytic method for the C11β-hydroxylation of 17α-hydroxyprogesterone by CYP103168 and / or its mutants, with a selectivity of approximately 99%; pathway b is the conventional process that utilizes filamentous fungi to catalyze the C11β-hydroxylation of RSA, with a selectivity of only approximately 20%.

[0036] The amino acid sequence of steroid hydroxylase CYP103168 is shown in SEQ ID NO: 1 in the sequence listing, and the nucleotide sequence of its encoding gene is shown in SEQ ID NO: 2 in the sequence listing.

[0037] Example 2: Construction of pESC-CYP103168 recombinant Saccharomyces cerevisiae vector

[0038] 1. The CYP103168 hydroxylation gene from Curvularia crescentis was synthesized by Suzhou Genewise Biotechnology Co., Ltd. and codon optimized according to the yeast system. Using the optimized CYP103168 gene as a template, upstream and downstream primers with BamHI and HindIII restriction sites were designed for PCR amplification. The primers were synthesized by Shanghai Qingke Biotechnology Co., Ltd.

[0039] F: CAAGGAGAAAAAACCCCGGATCCATGGACCCACAAACTGTTG

[0040] R:TAGCCGCGGTACCAAGCTTTTAAACAACAACTCTTTTAAA

[0041] (1) PCR reaction system:

[0042] Template: 1μL

[0043] DMSO: 1μL

[0044] Upstream primer: 1 μL

[0045] Downstream primer: 1 μL

[0046] Primer Star Mix: 25μL

[0047] Ultrapure water: 21μL

[0048] (2) PCR reaction conditions:

[0049] Pre-denaturation: 98℃ for 2 min

[0050]

[0051] 2. Purification of PCR products and vector enzyme digestion

[0052] The PCR products were placed in a water bath at 70°C for 20 minutes, and the PCR amplified fragments were recovered from the gel using a DNA gel recovery kit.

[0053] The pESC-ura empty vector plasmid was extracted using a plasmid extraction kit and then digested with BamHI and HindIII to obtain the vector backbone. Finally, the linearized vector was recovered by gel extraction.

[0054] Place the following enzyme digestion system in a 37°C water bath and digest for 1 hour.

[0055] pESC-ura plasmid: 20 μL

[0056] 10×cut smart buffer: 3μL

[0057] BamH I restriction endonuclease: 1.5 μL

[0058] HindIII restriction endonuclease: 1.5 μL

[0059] Ultrapure water: 4μL

[0060] 3. Connection with the carrier skeleton

[0061] The above-mentioned PCR-purified fragment and pESC fragment, which share the same BamHI and HindIII restriction sites, were seamlessly cloned and ligated. The construction of the pESC-CYP103168 recombinant Saccharomyces cerevisiae expression vector is shown in the figure below. Figure 2 As shown.

[0062] pESC-linearization carrier: 3μL

[0063] CYP103168 recovered fragment: 2μL

[0064] 2×Hieff Clone: ​​5μL

[0065] After ligation in a 50℃ water bath for 20 min, E. coli DH5α competent cells were transformed and plated on LA plates containing Ampr (100 μg / mL). The cells were then incubated at 37℃ for 12 h, and transformants were selected.

[0066] 4. Verify the transformant

[0067] After single colonies grew on the plate, they were picked for verification. Plasmid extraction was followed by double digestion with HindIII and EcoRI to confirm its correctness, thus obtaining the recombinant expression vector pESC-CYP103168 plasmid. The enzyme digestion verification image of the pESC-CYP103168 recombinant expression vector plasmid is shown below. Figure 3 As shown, lane 1 is the DL5000 marker, and lane 2 is the double enzyme digestion verification system of plasmid pESC-CYP103168d, which is consistent with the theoretical value.

[0068] Example 3: Construction of mutant plasmids L1 (H121A) and L2 (S367A)

[0069] Using pESC-CYP103168 plasmid as a template, rolling circle mutagenesis PCR was performed using H121A-F / R and S367A-F / R primers, respectively. The primers were synthesized by Shanghai Qingke Biotechnology Co., Ltd.

[0070] The site-directed mutagenesis primers are as follows:

[0071] H121A-F: ATATACTGCTTTGTCTATTGAAAATCCAACTGCTGCTGGT

[0072] H121A-R:GACAAAGCAGTATATTTAATTTCCAAATCTTCAGTC

[0073] S367A-F: CTATGACTGCTTTTACTAGAAGAGCTAGAAAAGGTATTAC

[0074] S367A-R: CTCTTCTAGTAAAAGCAGTCATAGTTGGACCAGTAAATC

[0075] Rolling circle mutant PCR system:

[0076] Template (pESC-CYP103168 plasmid): 0.4 μL

[0077] Upstream primer: 1 μL

[0078] Downstream primer: 1 μL

[0079] Primer Star Mix: 10μL

[0080] Ultrapure water: 7.6μL

[0081]

[0082] Site-directed mutagenesis was performed according to the above PCR amplification procedure to obtain the site-directed mutagenesis target vector fragments L1 (H121A) and L2 (S367A). The PCR products were verified by agarose gel electrophoresis to determine the band size. The verification results are shown in the agarose gel electrophoresis images of the PCR amplification bands of the L1 (H121A) and L2 (S367A) mutant plasmids. Figure 4 As shown, lane 1 is the wild-type plasmid pESC-CYP103168 control, lane 2 is the DL5000 marker, lane 3 is the H121A-F / R amplification product when constructing mutant L1, and lane 4 is the HS367A-F / R amplification product when constructing mutant L2.

[0083] The PCR product was digested with Dpn I enzyme for 3 hours and then recovered using a small-scale purification kit. After recovery, it was transformed into E. coli DH5α. Transformants were picked, cultured, and plasmids were extracted and sent to Shanghai Qingke Biotechnology Co., Ltd. for sequencing. The sequencing confirmed that the product was correct, and the mutant plasmids L1 (H121A) and L2 (S367A) were obtained.

[0084] Example 4: Transformation and Screening of Recombinant Yeast

[0085] Formula for auxotrophic culture media for yeast:

[0086] SD plates: 8g / L SD-Ura (Beijing Pankino Technology Co., Ltd.) powder, 20g / L glucose, 20g / L agar

[0087] SD liquid culture medium: 8 g / L SD-Ura powder, 20 g / L glucose

[0088] SG liquid medium: 8 g / L SD-Ura powder, 20 g / L galactose

[0089] Take 2 μL of recombinant plasmid pESC-CYP103168 and mutant plasmids L1 (H121A) and L2 (S367A), and transform them into Saccharomyces cerevisiae YPH499 competent cells in a lithium acetate-mediated manner. Add 300 μL of solution III from the Frozen-EA Yeast Transformation II™ Kit (ZymoResearch Biotechnology Co., Ltd.), and incubate at 30°C in a shaker for 1 h. Spread the transformed cells on uracil auxotrophic SD plates and incubate them at 30°C for 48 h. Single-clonal strains were selected and fermented in uracil-deficient SD liquid medium. When the growth OD value reached about 1.0, 1 mL of bacterial culture was centrifuged, the supernatant was discarded, and 50-100 μL of 50 mM NaOH solution was added depending on the amount of bacteria. After resuspending the bacteria, the culture was boiled in a water bath for 10 min. Then, 1 / 10 of the total sample volume of 1M Tris-HCl (pH 8.0) was added, and the culture was centrifuged at high speed. 2 μL of the supernatant was taken as the template solution. This template was used for PCR verification to screen for correct recombinant yeast transformants.

[0090] Example 5: Yeast cell catalysis and result detection

[0091] Transformants were picked from the corresponding recombinant yeast transformation plates and fermented in uracil-deficient SD liquid medium for about 20 hours until the OD value was about 1.0. At this time, the bacteria were collected by centrifugation at 4000 rpm for 5 minutes, and the medium was replaced 1:1 with uracil-deficient SG liquid medium and induced again at 30°C for 14 hours.

[0092] After induction, yeast cells were collected by centrifugation, resuspended in PBS buffer, and concentrated 20-fold to 200 μL, thus setting the transformation system to 200 μL. The steroid substrate 17α-hydroxyprogesterone was added at a rate of 0.125 g / L. Transformation was performed at 30°C with shaking for 20 h, followed by sampling and analysis. UPLC analysis results are shown below. Figure 5 The UPLC results of 17α-hydroxyprogesterone transformation by recombinant wild-type bacteria, mutants L1 (H121A) and L2 (S367A) are shown. In the chromatogram, peak 1 is the monohydroxylation byproduct 14α,17α-dihydroxyprogesterone (RT = 9.8 min); peak 2 is the monohydroxylation byproduct 11α,17α-dihydroxyprogesterone (RT = 10.1 min); and peak 3 is the monohydroxylation main product 11β,17α-dihydroxyprogesterone (RT = 10.6 min).

[0093] Post-sampling processing:

[0094] Take 20-40 μL of the conversion system and add methanol at a 1:1 ratio for extraction. After ultrasonic disruption for 15 min, centrifuge at 12000 rpm for 10 min and collect the supernatant for UPLC analysis.

[0095] The liquid phase conditions are as follows:

[0096] Mobile phase A: Water + 0.1% formic acid

[0097] Mobile phase B: Acetonitrile

[0098] Gradient elution, with the following flow ratios:

[0099] 3min 10% B

[0100] 5min 30% B

[0101] 7min 30% B

[0102] 9min 50% B

[0103] 11min 50% B

[0104] 12min 80% B

[0105] 13min 100% B

[0106] 16min 100% B

[0107] 18min 10% B

[0108] 20min 10% B

[0109] Temperature: 25℃;

[0110] Flow rate: 0.3 mL / min;

[0111] Injection volume: 10 μL;

[0112] Detection wavelength: 254nm;

[0113] Data acquisition time: 20 minutes;

[0114] according to Figure 5 The test results shown are analyzed as follows:

[0115] (1) Recombinant wild-type Saccharomyces cerevisiae (pESC-CYP103168) can be converted into 17α-hydroxyprogesterone by monohydroxylation to generate 14α,17α-dihydroxyprogesterone (product 1), 11α,17α-dihydroxyprogesterone (product 2) and 11β,17α-dihydroxyprogesterone (product 3), among which 11β,17α-dihydroxyprogesterone (product 3) is the main hydroxylated product, and its stereoselectivity and regioselectivity reach 95% (95.20±0.58).

[0116] (2) The main hydroxylated product of the conversion of 17α-hydroxyprogesterone by recombinant Saccharomyces cerevisiae mutants L1 (H121A) and L2 (S367A) to 11β,17α-dihydroxyprogesterone (product 3) at RT = 10.6 min was the compound with stereoselectivity and regioselectivity of 99% (99.80±0.45 and 99.02±0.69). The absorption peak area of ​​the by-products at RT = 9.8 min (14α,17α-dihydroxyprogesterone (product 1)) and 10.1 min (11α,17α-dihydroxyprogesterone (product 2) was significantly reduced or even disappeared.

[0117] SEQ ID NO: 1

[0118] MDPQTVGLVVRALQTTAIAAVLLAVWTYVPKLQLNAQLRKLPSLTPEGTTKARDKFMASARK

[0119] LYQDGYHKFRDSAYTLINENGNANVIVPPQFLPELRQLPDDVLSFPEALTEDLEIKYTHLSIENPT

[0120] AAGLIKKKLTPALPRLNPSICQDVDRAVKTYMPPCDDWTEVNINEKLLRIVAKVSGTIFVGPEL

[0121] ASDSDYLDAACFYTVDLMNAVTAMKKIRPWLKPFLASRTPEIIALRAREKHTERVLIPIVEQRIA

[0122] AKANDPNWQEPDDFLQWMLDMREGTESIQELAKTQLSLIFAAIHTTTMTVTNTMYTLAAMPE

[0123] YLEPLREEIRNVMLDEGGVITSRALQRMEKLDSYMKEVLRFTGPTMTSFTRRARKGITLSNGQY

[0124] IPAGVIIEVPSAAIYQDNAFYPSSDSFDGFRAYKARSTGKAADIARNQFVTSNEENLTFGYGRHACPGRFFAANEIKMMITRLILDYDIKMPNGEKERYPQIEIGKMSIPDPTKTLAFKRVVV*

[0125] SEQ ID NO: 2

[0126] ATGGACCCACAAACTGTTGGTTTGGTTGTTAGGGCTTTGCAAACTACTGCTATTGCTGCTGT

[0127] TTTGTTGGCTGTTTGGACTTATGTTCCAAAATTGCAATTGAATGCTCAATTGAGAAAATTGC

[0128] CATCTTTGACTCCTGAAGGTACTACTAAAGCTAGAGATAAATTTATGGCCTCTGCGAGAAA

[0129] GCTATATCAAGATGGTTACCACAAATTTAGAGACTCTGCGTACACTTTGATTAATGAAAATG

[0130] GTAATGCTAATGTTATTGTTCCACCACAATTTTTGCCTGAATTGAGACAATTGCCTGATGAT

[0131] GTTTTGTCTTTTCCTGAGGCTTTGACTGAAGATTTGGAAATTAAATATACTCATTTGTCTATT

[0132] GAAAATCCAACTGCTGCTGGTTTGATTAAAAAAAAATTGACTCCTGCTTTGCCAAGATTGA

[0133] ATCCATCTATTTGTCAAGATGTTGATAGAGCTGTTAAAACTTATATGCCCCCATGTGACGAC

[0134] TGGACAGAAGTCAACATTAACGAGAAATTGTTGCGGATTGTTGCTAAAGTTTCTGGTACTAT

[0135] TTTTGTTGGTCCTGAATTGGCTTCTGATTCTGATTATTTGGATGCTGCTTGTTTTTATACTGTT

[0136] GATTTGATGAATGCTGTTACTGCTATGAAAAAAATTAGACCATGGTTGAAACCATTTTTGGC

[0137] TTCTAGAACTCCTGAAATTATTGCTTTGAGAGCTAGAGAAAAACATACTGAAAGAGTTTTG

[0138] ATTCCAATTGTTGAACAAAGAATTGCTGCTAAAGCTAATGATCCAAATTGGCAAGAACCTG

[0139] ATGATTTTTTGCAATGGATGTTGGATATGAGAGAAGGTACTGAATCTATTCAAGAATTGGCT

[0140] AAAACTCAATTGTCTTTGATTTTCGCTGCTATACATACTACTACTATGACTGTTACTAATACT

[0141] ATGTATACTTTGGCTGCTATGCCTGAATATTTGGAACCATTGAGAGAAGAAATTAGAAATG

[0142] TTATGTTGGATGAAGGTGGTGTTATTACTTCTCGCGCTTTGCAAAGAATGGAAAAATTGGAT

[0143] TCTTATATGAAAGAAGTTTTGAGATTTACTGGTCCAACTATGACTTCTTTTACTAGAAGAGC

[0144] TAGAAAAGGTATTACTTTGTCTAATGGTCAATATATTCCTGCTGGTGTTATTATTGAAGTTC

[0145] CATCTGCTGCTATTTATCAAGATAATGCTTTTTATCCATCTTCTGATTCTTTTGATGGTTTTA

[0146] GAGCTTATAAAGCTAGATCTACTGGTAAAGCTGCTGATATTGCTAGAAATCAATTTGTTACT

[0147] TCTAATGAAGAAAATTTGACTTTTGGTTATGGTAGACATGCATGTCCTGGTAGATTCTTCGC

[0148] TGCGAATGAGATTAAATGATGATTACTCGATTAATCTTGGATTACGACATCAAGATGCCA

[0149] AATGGTGAAAAGGAAAGGTATCCCCAAATTGAAATTGGTAAAATGTCTATTCCTGATCCAA

[0150] CTAAAACTTTGGCTTTTAAAAGAGTTGTTGTTTAA

[0151] SEQ ID NO: 3

[0152] MDPQTVGLVVRALQTTAIAVLLAVWTYVPKLQLNAQLRKLPSLTPEGTTKARDKFMASARK

[0153] LYQDGYHKFRDSAYTLINENGNANVIVPPQFLPELRQLPDDVLSFPEALTEDLEIKYTALSIENPT

[0154] AAGLIKKKLTPALPRLNPSICQDVDRAVKTYMPPCDDWTEVNINEKLLRIVAKVSGTIFVGPEL

[0155] ASDSDYLDAACFYTVDLMNAVTAMKKIRPWLKPFLASRTPEIIALRAREKHTERVLIPIVEQRIA

[0156] AKANDPNWQEPDDFLQWMLDMREGTESIQELAKTQLSLIFAAIHTTTMTVTNTMYTLAAMPE

[0157] YLEPLREEIRNVMLDEGGGVITSRALQRMEKLDSYMKEVLRFTGPTMTSFTRRARKGITLSNGQY

[0158] IPAGVIIEVPSAAIYQDNAPYSSSDSFDGFRAYKARSTGKAADIARNQFVTSNEENLTFGYGRHACPGRFFAANEIKMMITRLILDYDIKMPNGEKERYPQIEIGKMSIPDPTKTLAFKRVVV*

[0159] SEQ ID NO: 4

[0160] ATGGACCCACAAACTGTTGGTTTGGTTGTTAGGGCTTTGCAAACTACTGCTATTGCTGCTGT

[0161] TTTGTTGGCTGTTTGGACTTATGTTCCAAAATTGCAATTGAATGCTCAATTGAGAAAATTGC

[0162] CATCTTTGACTCCTGAAGGTACTACTAAAGCTAGAGATAAATTTATGGCCTCTGCGAGAAA

[0163] GCTATATCAAGATGGTTACCACAAATTTAGAGACTCTGCGTACACTTTGATTAATGAAAATG

[0164] GTAATGCTAATGTTATTGTTCCACCACAATTTTTGCCTGAATTGAGACAATTGCCTGATGAT

[0165] GTTTTGTCTTTTCCTGAGGCTTTGACTGAAGATTTGGAAATTAAATATACTGCTTTGTCTATT

[0166] GAAAATCCAACTGCTGCTGGTTTGATTAAAAAAAAATTGACTCCTGCTTTGCCAAGATTGA

[0167] ATCCATCTATTTGTCAAGATGTTGATAGAGCTGTTAAAACTTATATGCCCCCATGTGACGAC

[0168] TGGACAGAAGTCAACATTAACGAGAAATTGTTGCGGATTGTTGCTAAAGTTTCTGGTACTAT

[0169] TTTTGTTGGTCCTGAATTGGCTTCTGATTCTGATTATTTGGATGCTGCTTGTTTTTATACTGTT

[0170] GATTTGATGAATGCTGTTACTGCTATGAAAAAAATTAGACCATGGTTGAAACCATTTTTGGC

[0171] TTCTAGAACTCCTGAAATTATTGCTTTGAGAGCTAGAGAAAAACATACTGAAAGAGTTTTG

[0172] ATTCCAATTGTTGAACAAAGAATTGCTGCTAAAGCTAATGATCCAAATTGGCAAGAACCTG

[0173] ATGATTTTTTGCAATGGATGTTGGATATGAGAGAAGGTACTGAATCTATTCAAGAATTGGCT

[0174] AAAACTCAATTGTCTTTGATTTTCGCTGCTATACATACTACTACTATGACTGTTACTAATACT

[0175] ATGTATACTTTGGCTGCTATGCCTGAATATTTGGAACCATTGAGAGAAGAAATTAGAAATG

[0176] TTATGTTGGATGAAGGTGGTGTTATTACTTCTCGCGCTTTGCAAAGAATGGAAAAATTGGAT

[0177] TCTTATATGAAAGAAGTTTTGAGATTTACTGGTCCAACTATGACTTCTTTTACTAGAAGAGC

[0178] TAGAAAAGGTATTACTTTGTCTAATGGTCAATATATTCCTGCTGGTGTTATTATTGAAGTTC

[0179] CATCTGCTGCTATTTATCAAGATAATGCTTTTTATCCATCTTCTGATTCTTTTGATGGTTTTA

[0180] GAGCTTATAAAGCTAGATCTACTGGTAAAGCTGCTGATATTGCTAGAAATCAATTTGTTACT

[0181] TCTAATGAAGAAAATTTGACTTTTGGTTATGGTAGACATGCATGTCCTGGTAGATTCTTCGC

[0182] TGCGAATGAGATTAAATGATGATTACTCGATTAATCTTGGATTACGACATCAAGATGCCA

[0183] AATGGTGAAAAGGAAAGGTATCCCCAAATTGAAATTGGTAAAATGTCTATTCCTGATCCAA

[0184] CTAAAACTTTGGCTTTTAAAAGAGTTGTTGTTTAA

[0185] SEQ ID NO: 5

[0186] MDPQTVGLVVRALQTTAIAVLLAVWTYVPKLQLNAQLRKLPSLTPEGTTKARDKFMASARK

[0187] LYQDGYHKFRDSAYTLINENGNANVIVPPQFLPELRQLPDDVLSFPEALTEDLEIKYTHLSIENPT

[0188] AAGLIKKKLTPALPRLNPSICQDVDRAVKTYMPPCDDWTEVNINEKLLRIVAKVSGTIFVGPEL

[0189] ASDSDYLDAACFYTVDLMNAVTAMKKIRPWLKPFLASRTPEIIALRAREKHTERVLIPIVEQRIA

[0190] AKANDPNWQEPDDFLQWMLDMREGTESIQELAKTQLSLIFAAIHTTTMTVTNTMYTLAAMPE

[0191] YLEPLREEIRNVMLDEGGVITSRALQRMEKLDSYMKEVLRFTGPTMTAFTRRARKGITLSNGQY

[0192] IPAGVIIEVPSAAIYQDNAPYSSSDSFDGFRAYKARSTGKAADIARNQFVTSNEENLTFGYGRHACPGRFFAANEIKMMITRLILDYDIKMPNGEKERYPQIEIGKMSIPDPTKTLAFKRVVV*

[0193] SEQ ID NO: 6

[0194] ATGGACCCACAAACTGTTGGTTTGGTTGTTAGGGCTTTGCAAACTACTGCTATTGCTGCTGT

[0195] TTTGTTGGCTGTTTGGACTTATGTTCCAAAATTGCAATTGAATGCTCAATTGAGAAAATTGC

[0196] CATCTTTGACTCCTGAAGGTACTACTAAAGCTAGAGATAAATTTATGGCCTCTGCGAGAAA

[0197] GCTATATCAAGATGGTTACCACAAATTTAGAGACTCTGCGTACACTTTGATTAATGAAAATG

[0198] GTAATGCTAATGTTATTGTTCCACCACAATTTTTGCCTGAATTGAGACAATTGCCTGATGAT

[0199] GTTTTGTCTTTTCCTGAGGCTTTGACTGAAGATTTGGAAATTAAATATACTCATTTGTCTATT

[0200] GAAAATCCAACTGCTGCTGGTTTGATTAAAAAAAAATTGACTCCTGCTTTGCCAAGATTGA

[0201] ATCCATCTATTTGTCAAGATGTTGATAGAGCTGTTAAAACTTATATGCCCCCATGTGACGAC

[0202] TGGACAGAAGTCAACATTAACGAGAAATTGTTGCGGATTGTTGCTAAAGTTTCTGGTACTAT

[0203] TTTTGTTGGTCCTGAATTGGCTTCTGATTCTGATTATTTGGATGCTGCTTGTTTTTATACTGTT

[0204] GATTTGATGAATGCTGTTACTGCTATGAAAAAAATTAGACCATGGTTGAAACCATTTTTGGC

[0205] TTCTAGAACTCCTGAAATTATTGCTTTGAGAGCTAGAGAAAAACATACTGAAAGAGTTTTG

[0206] ATTCCAATTGTTGAACAAAGAATTGCTGCTAAAGCTAATGATCCAAATTGGCAAGAACCTG

[0207] ATGATTTTTTGCAATGGATGTTGGATATGAGAGAAGGTACTGAATCTATTCAAGAATTGGCT

[0208] AAAACTCAATTGTCTTTGATTTTCGCTGCTATACATACTACTACTATGACTGTTACTAATACT

[0209] ATGTATACTTTGGCTGCTATGCCTGAATATTTGGAACCATTGAGAGAAGAAATTAGAAATG

[0210] TTATGTTGGATGAAGGTGGTGTTATTACTTCTCGCGCTTTGCAAAGAATGGAAAAATTGGAT

[0211] TCTTATATGAAAGAAGTTTTGAGATTTACTGGTCCAACTATGACTGCTTTTACTAGAAGAGC

[0212] TAGAAAAGGTATTACTTTGTCTAATGGTCAATATATTCCTGCTGGTGTTATTATTGAAGTTC

[0213] CATCTGCTGCTATTTATCAAGATAATGCTTTTTATCCATCTTCTGATTCTTTTGATGGTTTTA

[0214] GAGCTTATAAAGCTAGATCTACTGGTAAAGCTGCTGATATTGCTAGAAATCAATTTGTTACT

[0215] TCTAATGAAGAAAATTTGACTTTTGGTTATGGTAGACATGCATGTCCTGGTAGATTCTTCGC

[0216] TGCGAATGAGATTAAAATGATGATTACTCGATTAATCTTGGATTACGACATCAAGATGCCA

[0217] AATGGTGAAAAGGAAAGGTATCCCCAAATTGAAATTGGTAAAATGTCTATTCCTGATCCAA

[0218] CTAAAACTTTGGCTTTTAAAAGAGTTGTTGTTTAA

[0219] The preferred embodiments of the present invention have been described in detail above. It should be understood that those skilled in the art can make numerous modifications and variations based on the concept of the present invention without creative effort. Therefore, all technical solutions that can be obtained by those skilled in the art based on the concept of the present invention through logical analysis, reasoning, or limited experimentation on the basis of existing technology should be within the scope of protection defined by the claims.

Claims

1. A mutant of a steroid hydroxylase, characterized in that, The mutant is mutant L1 or / and mutant L2, the amino acid sequence of mutant L1 is shown as SEQ ID NO: 3 in the sequence listing, and the amino acid sequence of mutant L2 is shown as SEQ ID NO: 5 in the sequence listing.

2. A recombinant yeast strain, characterized in that, The recombinant yeast strain was obtained by introducing the coding gene of mutant L1 or / and mutant L2 into Saccharomyces cerevisiae; the coding gene of mutant L1 is shown as SEQ ID NO: 4 in the sequence listing, and the coding gene of mutant L2 is shown as SEQ ID NO: 6 in the sequence listing.

3. The application of the mutant as described in claim 1 in catalyzing the C11β-hydroxylation of steroid 17α-hydroxyprogesterone.

4. The application of a recombinant yeast strain as described in claim 3 in catalyzing the C11β-hydroxylation of steroid 17α-hydroxyprogesterone.

5. An application as described in claim 4, characterized in that, The product is an 11β,17α-hydroxyprogesterone steroid compound.

6. The application of a substrate 17α-hydroxyprogesterone in the C11β-hydroxylation of steroid 17α-hydroxyprogesterone catalyzed by steroid hydroxylase, characterized in that, The steroid hydroxylases are wild-type CYP103168, mutant L1 / H121A, and mutant L2 / S367A; the amino acid sequence of the steroid hydroxylase CYP103168 is shown in SEQ ID NO: 1 in the sequence listing, the amino acid sequence of the mutant L1 / H121A is shown in SEQ ID NO: 3 in the sequence listing, and the amino acid sequence of the mutant L2 / S367A is shown in SEQ ID NO: 5 in the sequence listing.

Citation Information

Patent Citations

  • Method for preparing 11beta-hydroxyl-1,4-diene-3,20-dione steroid through co-fermentation of curvularia lunata and arthrobacterium

    CN105779553A